FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3181526998> ?p ?o ?g. }

• W3181526998 abstract "Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium-glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this study, we compared the risk of several CV outcomes between new users of SGLT2i and other glucose-lowering drugs (oGLDs) in Catalonia, Spain.CVD-REAL Catalonia was a retrospective cohort study using real-world data routinely collected between 2013 and 2016. The cohorts of new users of SGLT2i and oGLDs were matched by propensity score on a 1:1 ratio. We compared the incidence rates and hazard ratio (HR) for all-cause death, hospitalization for heart failure, chronic kidney disease, and modified major adverse CV event (MACE; all-cause mortality, myocardial infarction, or stroke).After propensity score matching, 12,917 new users were included in each group. About 27% of users had a previous history of CV disease. In the SGLT2i group, the exposure time was 60% for dapagliflozin, 26% for empagliflozin and 14% for canagliflozin. The use of SGLT2i was associated with a lower risk of heart failure (HR: 0.59; 95% confidence interval [CI] 0.47-0.74; p < 0.001), all-cause death (HR = 0.41; 95% CI 0.31-0.54; p < 0.001), all-cause death or heart failure (HR = 0.55; 95% CI 0.47-0.63; p < 0.001), modified MACE (HR = 0.62; 95% CI 0.52-0.74; p < 0.001), and chronic kidney disease (HR = 0.66; 95% CI 0.54-0.80; p < 0.001).In this large, retrospective observational study of patients with T2DM from a Catalonia, initiation of SGLT-2i was associated with lower risk of mortality, as well as heart failure and CKD." @default.
• W3181526998 created "2021-07-19" @default.
• W3181526998 creator A5008251932 @default.
• W3181526998 creator A5012291664 @default.
• W3181526998 creator A5014656891 @default.
• W3181526998 creator A5021845200 @default.
• W3181526998 creator A5027701342 @default.
• W3181526998 creator A5034010147 @default.
• W3181526998 creator A5034583515 @default.
• W3181526998 creator A5045843608 @default.
• W3181526998 creator A5049181124 @default.
• W3181526998 creator A5052309689 @default.
• W3181526998 creator A5052533254 @default.
• W3181526998 date "2021-07-09" @default.
• W3181526998 modified "2023-10-18" @default.
• W3181526998 title "Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia" @default.
• W3181526998 cites W1526927233 @default.
• W3181526998 cites W172609984 @default.
• W3181526998 cites W1809230663 @default.
• W3181526998 cites W1991893058 @default.
• W3181526998 cites W2035433295 @default.
• W3181526998 cites W2036936011 @default.
• W3181526998 cites W2064130493 @default.
• W3181526998 cites W2066015134 @default.
• W3181526998 cites W2077755583 @default.
• W3181526998 cites W2118029334 @default.
• W3181526998 cites W2120291589 @default.
• W3181526998 cites W2139577967 @default.
• W3181526998 cites W2147663252 @default.
• W3181526998 cites W2150561315 @default.
• W3181526998 cites W2154038775 @default.
• W3181526998 cites W2186322500 @default.
• W3181526998 cites W2284028653 @default.
• W3181526998 cites W2301210108 @default.
• W3181526998 cites W2306356166 @default.
• W3181526998 cites W2500198996 @default.
• W3181526998 cites W2519686100 @default.
• W3181526998 cites W2585095576 @default.
• W3181526998 cites W2610311410 @default.
• W3181526998 cites W2614137535 @default.
• W3181526998 cites W2617287176 @default.
• W3181526998 cites W2743267681 @default.
• W3181526998 cites W2745253866 @default.
• W3181526998 cites W2768451744 @default.
• W3181526998 cites W2800277129 @default.
• W3181526998 cites W2801716806 @default.
• W3181526998 cites W2802245520 @default.
• W3181526998 cites W2806521060 @default.
• W3181526998 cites W2808467887 @default.
• W3181526998 cites W2888252873 @default.
• W3181526998 cites W2895533920 @default.
• W3181526998 cites W2899764361 @default.
• W3181526998 cites W2900442056 @default.
• W3181526998 cites W2907474302 @default.
• W3181526998 cites W2916668213 @default.
• W3181526998 cites W2917793655 @default.
• W3181526998 cites W2939222610 @default.
• W3181526998 cites W2941506137 @default.
• W3181526998 cites W2949665037 @default.
• W3181526998 cites W2967839838 @default.
• W3181526998 cites W2973090108 @default.
• W3181526998 cites W2981101186 @default.
• W3181526998 cites W2995016571 @default.
• W3181526998 cites W2996130540 @default.
• W3181526998 cites W3016493807 @default.
• W3181526998 cites W3021208389 @default.
• W3181526998 cites W3035689851 @default.
• W3181526998 cites W3088173406 @default.
• W3181526998 cites W3152913209 @default.
• W3181526998 cites W4234015579 @default.
• W3181526998 cites W4246340431 @default.
• W3181526998 doi "https://doi.org/10.1186/s12933-021-01323-5" @default.
• W3181526998 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8272340" @default.
• W3181526998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34243779" @default.
• W3181526998 hasPublicationYear "2021" @default.
• W3181526998 type Work @default.
• W3181526998 sameAs 3181526998 @default.
• W3181526998 citedByCount "12" @default.
• W3181526998 countsByYear W31815269982022 @default.
• W3181526998 countsByYear W31815269982023 @default.
• W3181526998 crossrefType "journal-article" @default.
• W3181526998 hasAuthorship W3181526998A5008251932 @default.
• W3181526998 hasAuthorship W3181526998A5012291664 @default.
• W3181526998 hasAuthorship W3181526998A5014656891 @default.
• W3181526998 hasAuthorship W3181526998A5021845200 @default.
• W3181526998 hasAuthorship W3181526998A5027701342 @default.
• W3181526998 hasAuthorship W3181526998A5034010147 @default.
• W3181526998 hasAuthorship W3181526998A5034583515 @default.
• W3181526998 hasAuthorship W3181526998A5045843608 @default.
• W3181526998 hasAuthorship W3181526998A5049181124 @default.
• W3181526998 hasAuthorship W3181526998A5052309689 @default.
• W3181526998 hasAuthorship W3181526998A5052533254 @default.
• W3181526998 hasBestOaLocation W31815269981 @default.
• W3181526998 hasConcept C126322002 @default.
• W3181526998 hasConcept C127413603 @default.
• W3181526998 hasConcept C134018914 @default.
• W3181526998 hasConcept C17923572 @default.
• W3181526998 hasConcept C207103383 @default.
• W3181526998 hasConcept C2775887513 @default.
• W3181526998 hasConcept C2777180221 @default.

• next